Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

However, recent mixed results from other pipeline candidates have raised questions about the company's ability to successfully bring new products to market beyond Ingrezza. Neurocrine's strategy ...

About Neurocrine Biosciences Neurocrine Biosciences ... risks related to the development of our product candidates; risks associated with our dependence on third parties for development ...

Neurocrine Biosciences (NasdaqGS:NBIX) announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, ...

Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. We sell different types of products and ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates. Overall, the quarter showcased strong ...

Neurocrine Biosciences disclaims any obligation ... We sell different types of products and services to both investment professionals and individual investors. These products and services are ...

However, recent mixed results from other pipeline candidates have raised questions about the company's ability to successfully bring new products to market beyond Ingrezza. Neurocrine's strategy ...